Molecular mechanisms of depression: Perspectives on new treatment strategies

Cellular Physiology and Biochemistry

Volumn 31, Issue 6, 2013, Pages 761-777

  Lang, Undine E ^a,b   Borgwardt, Stefan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

BDNF; Cardiovascular; Depression; Glutamate; Inflammation; Metabolic; Sleep; Stress

Indexed keywords

4 AMINOBUTYRIC ACID; ARGIPRESSIN; BETA CATENIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLECYSTOKININ; CHROMIUM; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; CYANOCOBALAMIN; D DIMER; DEXAMETHASONE; FOLIC ACID; GALANIN; GASTRIN RELEASING PEPTIDE; GHRELIN; GLUCOCORTICOID RECEPTOR; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; KETAMINE; LEPTIN; LEPTIN RECEPTOR; MELATONIN; MINERALOCORTICOID RECEPTOR; NEUROPEPTIDE Y; NORADRENALIN; PLACEBO; PYRIDOXINE; SEROTONIN; SOMATOMEDIN; UNINDEXED DRUG; ACUTE PHASE PROTEIN; ALPHA INTERFERON; C REACTIVE PROTEIN; CORTICOSTEROID; CORTICOTROPIN; CYCLOOXYGENASE 2; HAPTOGLOBIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; MECOBALAMIN; MONOUNSATURATED FATTY ACID; OLIVE OIL; OMEGA 3 FATTY ACID; PROSTAGLANDIN E2; SPHINGOMYELIN PHOSPHODIESTERASE; SUBSTANCE P; TESTOSTERONE; THYROTROPIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; ANHEDONIA; ANOREXIA; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APPETITE; ARTERIAL PRESSURE; BEHAVIOR CHANGE; BLOOD PRESSURE REGULATION; BLOOD VISCOSITY; BODY TEMPERATURE; BRAIN FUNCTION; BRAIN REGION; CALORIC INTAKE; CELL METABOLISM; CELL PROLIFERATION; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; CHRONIC STRESS; CIRCADIAN RHYTHM; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CORPUS STRIATUM; CORTICOSTERONE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIETARY INTAKE; DIGESTIVE FUNCTION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; ENDOTHELIAL PROGENITOR CELL; ENTEROENDOCRINE CELL; ESCAPE BEHAVIOR; EXTRACELLULAR SPACE; FEVER; FOLIC ACID DEFICIENCY; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GASTROINTESTINAL TRANSIT; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEART INFARCTION; HEART RATE VARIABILITY; HUMAN; HUMORAL IMMUNITY; HYPERALGESIA; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHYROIDISM; INSULIN SENSITIVITY; LETHARGY; LIPID METABOLISM; LIPID PEROXIDATION; LOCOMOTION; LOCUS CERULEUS; MAJOR DEPRESSION; MALAISE; MANIA; MENTAL FUNCTION; META ANALYSIS; METABOLIC SYNDROME X; MONOTHERAPY; MOOD DISORDER; MULTIPLE SCLEROSIS; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORADRENERGIC NERVE; NUCLEUS ACCUMBENS; OBESITY; OSSIFICATION; OVERNUTRITION; OXIDATIVE STRESS; PILOT STUDY; PLASMA VOLUME; PRIORITY JOURNAL; PSORIASIS; PSYCHOLOGICAL WELL BEING; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REPRODUCTIVE SUCCESS; REVIEW; RISK FACTOR; SEROTONIN BRAIN LEVEL; SLEEP DISORDER; SOCIAL BEHAVIOR; SOMNOLENCE; STEM CELL; STOMACH EMPTYING; SUBCLINICAL HYPOTHYROIDISM; SUICIDE; SUPRACHIASMATIC NUCLEUS; SURVIVAL FACTOR; SYMPATHETIC TONE; SYNAPTIC EFFICACY; SYNAPTIC MEMBRANE; SYNAPTIC TRANSMISSION; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC HYPERTENSION; THROMBOCYTE ACTIVATION; WEIGHT GAIN; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; BRAIN SIZE; DEPRESSION; FISH; FRUIT; HIPPOCAMPUS; LEGUME; NUT; NUTRITION; VEGETABLE;

MAMMALIA;

EID: 84878352105     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350094     Document Type: Review

References (167)

1. Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A: Depression and the risk for cardiovascular diseases: systematic review and meta-analysis. Int J Geriatr Psychiatry 2007;22:613-626. (Pubitemid 47180373)
2. Ramasubbu R, Patten SB: Effect of depression on stroke morbidity and mortality. Can J Psychiatry 2003;48:250-257. (Pubitemid 36733832)
3. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L: Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol 2003;60:753-759. (Pubitemid 36569895)
4. Hesdorffer DC, Hauser WA, Annegers JF, Cascino G: Major depression is a risk factor for seizures in older adults. Ann Neurol 2000;47:246-249. (Pubitemid 30078574)
5. Nouwen A, Lloyd CE, Pouwer F: Depression and type 2 diabetes over the lifespan: a meta-analysis. Response to Mezuk et al. Diabetes Care 2009;32:e56-e57.
6. Penninx BW, Guralnik JM, Pahor M, Ferrucci L, Cerhan JR, Wallace RB, Havlik RJ: Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 1998;90:1888-1893. (Pubitemid 29014222)
7. Keller MB, Hirschfeld RM, Demyttenaere K, Baldwin DS: Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol 2002;17:265-271. (Pubitemid 35283713)
8. Hendrickx H, McEwen BS, Ouderaa F: Metabolism, mood and cognition in aging: the importance of lifestyle and dietary intervention. Neurobiol Aging 2005;26:1-5.
9. Shelton RC, Miller AH: Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol 2010;91:275-299.
10. Bouwman V, Adriaanse MC, van 't Riet E, Snoek FJ, Dekker JM, Nijpels G: Depression, anxiety and glucose metabolism in the general dutch population: the new Hoorn study. PLoS One 2010;5:e9971.
11. McIntyre RS, Soczynska JK, Konarski JZ, Woldeyohannes HO, Law CW, Miranda A, Fulgosi D, Kennedy SH: Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"? Ann Clin Psychiatry 2007;19:257-266.
12. Wexler DJ, Porneala B, Chang Y, Huang ES, Huffman JC, Grant RW: Diabetes differentially affects depression and self-rated health by age in the US. Diabetes Care 2012;35:1575-1577.
13. Gois C, Akiskal H, Akiskal K, Figueira ML: The relationship between temperament, diabetes and depression. J Affect Disord 2012;142:S67-71.
14. Chaudhri OB, Wynne K, Bloom SR: Can gut hormones control appetite and prevent obesity? Diabetes Care 2008;31:S284-289.
15. Häfner S, Baumert J, Emeny RT, Lacruz ME, Thorand B, Herder C, Koenig W, Rupprecht R, Ladwig KH: Sleep disturbances and depressed mood: a harmful combination associated with increased leptin levels in women with normal weight. Biol Psychol 2012;89:163-169.
16. Garza JC, Guo M, Zhang W, Lu XY: Leptin restores adult hippocampal neurogenesis in a chronic unpredictable stress model of depression and reverses glucocorticoid-induced inhibition of GSK-3β/β-catenin signaling. Mol Psychiatry 2012;17:790-808.
17. Krugel U, Schraft T, Kittner H, Kiess W, Illes P: Basal and feeding-evoked dopamine release in the rat nucleus accumbens is depressed by leptin. Eur J Pharmacol 2003;482:185-187. (Pubitemid 37505943)
18. Fulton S, Pissios P, Manchon RP, Stiles L, Frank L, Pothos EN, Maratos-Flier E, Flier JS: Leptin regulation of the mesoaccumbens dopamine pathway. Neuron 2006;51:811-822. (Pubitemid 44374918)
19. Hommel JD, Trinko R, Sears RM, Georgescu D, Liu ZW, Gao XB, Thurmon JJ, Marinelli M, DiLeone RJ: Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 2006;51:801-810. (Pubitemid 44374908)
20. Lutter M, Nestler EJ: Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr 2009;139:629-632.
21. Kluge M, Schüssler P, Dresler M, Schmidt D, Yassouridis A, Uhr M, Steiger A: Effects of ghrelin on psychopathology, sleep and secretion of cortisol and growth hormone in patients with major depression. J Psychiatr Res 2011;45:421-426.
22. Lutter M, Sakata I, Osborne-Lawrence S, Rovinsky SA, Anderson JG, Jung S, Birnbaum S, Yanagisawa M, Elmquist JK, Nestler EJ, Zigman JM: The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci 2008;11:752-753. (Pubitemid 351896679)
23. Schellekens H, Finger BC, Dinan TG, Cryan JF: Ghrelin signalling and obesity: at the interface of stress, mood and food reward. Pharmacol Ther 2012;135:316-326.
24. Koliaki C, Kokkinos A, Tentolouris N, Katsilambros N: The effect of ingested macronutrients on postprandial ghrelin response: a critical review of existing literature data. Int J Pept 2010;2010. pii:710852.
25. Aberg MA, Aberg ND, Hedbacker H, Oscarsson J, Eriksson PS: Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J Neurosci 2000;20:2896-2903. (Pubitemid 30220315)
26. Trejo JL, Carro E, Torres-Aleman I: Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J Neurosci 2001;21:1628-1634. (Pubitemid 32182203)
27. Cline BH, Steinbusch HW, Malin D, Revishchin AV, Pavlova GV, Cespuglio R, Strekalova T: The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: possible role of insulin-like growth factor 2. BMC Neurosci 2012;13:110.
28. Anderson MF, Aberg MA, Nilsson M, Eriksson PS: Insulin-like growth factor-I and neurogenesis in the adult mammalian brain. Brain Res Dev Brain Res 2002;134:115-122. (Pubitemid 34310242)
29. Hoshaw BA, Malberg JE, Lucki I: Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005;1037:204-208. (Pubitemid 40362398)
30. Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE, Rosenzweig-Lipson S: Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 2007;32:2360-2368. (Pubitemid 47587671)
31. Becker C, Zeau B, Rivat C, Blugeot A, Hamon M, Benoliel JJ: Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin. Mol Psychiatry 2008;13:1079-1092.
32. Ströhle A, Romeo E, di Michele F, Pasini A, Hermann B, Gajewsky G, Holsboer F, Rupprecht R: Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 2003;60:161-168. (Pubitemid 36173122)
33. Arey RN, Enwright JF 3rd, Spencer SM, Falcon E, Ozburn AR, Ghose S, Tamminga C, McClung CA: An important role for Cholecystokinin, a CLOCK target gene, in the development and treatment of manic-like behaviors. Mol Psychiatry 2013;doi: 10.1038/mp.2013.47.
34. Roesler R, Henriques JA, Schwartsmann G: Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders. CNS Neurol Disord Drug Targets 2006;5:197-204. (Pubitemid 43796620)
35. Horacek J, Kuzmiakova M, Hoschl C, Andel M, Bahbonh R: The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology 1999;24:785-797. (Pubitemid 29461052)
36. McCarty MF: Longevity effect of chromium picolinate - 'rejuvenation' of hypothalamic function? Med Hypotheses 1994;43:253-265. (Pubitemid 24324125)
37. McLeod MN, Gaynes BN, Golden RN: Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. J Clin Psychiatry 1999;60:237-240. (Pubitemid 29193921)
38. McLeod MN, Golden RN: Chromium treatment of depression. Int J Neuropsychopharmacol 2000;3:311-314. (Pubitemid 32056624)
39. Davidson JR, Abraham K, Connor KM, McLeod MN: Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry 2003;53:261-264. (Pubitemid 36135938)
40. Gentleman SM, Falkai P, Bogerts B, Herrero MT, Polak JM, Roberts GW: Distribution of galanin-like immunoreactivity in the human brain. Brain Res 1989;505:311-315. (Pubitemid 20013170)
41. Kozlovsky N, Matar MA, Kaplan Z, Zohar J, Cohen H: The role of the galaninergic system in modulating stress-related responses in an animal model of posttraumatic stress disorder. Biol Psychiatry 2009;65:383-391.
42. Tatemoto K, Carlquist M, Mutt V: Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982;296:659-660. (Pubitemid 12089070)
43. Brothers SP, Wahlestedt C: Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol Med 2010;2:429-439.
44. Wu G, Feder A, Wegener G, Bailey C, Saxena S, Charney D, Mathé AA: Central functions of neuropeptide Y in mood and anxiety disorders. Expert Opin Ther Targets 2011;15:1317-1331.
45. Liao GY, An JJ, Gharami K, Waterhouse EG, Vanevski F, Jones KR, Xu B: Dendritically targeted Bdnf mRNA is essential for energy balance and response to leptin. Nat Med 2012;18:564-571.
46. Holsboer F, Ising M: Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol 2010;61:81-109.
47. Feder A, Nestler EJ, Charney DS: Psychobiology and molecular genetics of resilience. Nat Rev Neurosci 2009;10:446-457.
48. Kling MA, Coleman VH, Schulkin J: Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? Depress Anxiety 2009;26:641-649.
49. Boswell EB, Anfinson TH, Nemeroff CB: Depression associated with endocrine disorders; In Robertson MM, Katona CLE (eds): Depression and physical illness. England: Wiley, Chichester, 1997, pp 256-292.
50. Bahls SC, de Carvalho GA: The relation between thyroid function and depression: a review. Rev Bras Psiquiatr 2004;26:41-49. (Pubitemid 38419358)
51. Cleare AJ, McGregor A, O'Keane V: Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin Endocrinol 1995;43:713-719. (Pubitemid 26016802)
52. Frey A, Lampert A, Dietz K, Striebich S, Locher C, Fedorenko O, Möhle R, Gallinat J, Lang F, Lang UE: Thyrotropin serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychobiology 2007;56:123-126. (Pubitemid 351340024)
53. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC: Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001;158:1617-1622. (Pubitemid 32923653)
54. Carvalho AF, Machado JR, Cavalcante JL: Augmentation strategies for treatment-resistant depression. Curr Opin Psychiatry 2009;22:7-12.
55. Dayan CM, Panicker V: Novel insights into thyroid hormones from the study of common genetic variation. Nat Rev Endocrinol 2009;5:211-218.
56. Nemeroff CB, Goldschmidt-Clermont PJ: Heartache and heartbreak - the link between depression and cardiovascular disease. Nat Rev Cardiol 2012;9:526-539.
57. Lippi G, Montagnana M, Favaloro EJ, Franchini M: Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Semin Thromb Hemost 2009;35:325-333.
58. Tiemeier H, van Dijck W, Hofman A, Witteman JC, Stijnen T, Breteler MM: Relationship between atherosclerosis and late-life depression: the Rotterdam Study. Arch Gen Psychiatry 2004;61:369-376. (Pubitemid 38451546)
59. Cizza G, Ronsaville DS, Kleitz H, Eskandari F, Mistry S, Torvik S, Sonbolian N, Reynolds JC, Blackman MR, Gold PW, Martinez PE; P.O.W.E.R (Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression) Study Group: Clinical subtypes of depression are associated with specific metabolic parameters and circadian endocrine profiles in women: the power study. PLoS One 2012;7:e28912.
60. Kabir AA, Srinivasan SR, Sultana A, Chen W, Wei CY, Berenson GS: Association between depression and intima-media thickness of carotid bulb in asymptomatic young adults. Am J Med 2009;122:1151.e1-8.
61. Smith PJ, Blumenthal JA, Babyak MA, Doraiswamy PM, Hinderliter A, Hoffman BM, Waugh R, Sherwood A: Intima-media thickness and age of first depressive episode. Biol Psychol 2009;80:361-364.
62. Baghai TC, Varallo-Bedarida G, Born C, Häfner S, Schüle C, Eser D, Rupprecht R, Bondy B, von Schacky C: Major depressive disorder is associated with cardiovascular risk factors and low Omega-3 Index. J Clin Psychiatry 2011;72:1242-1247.
63. Geiser F, Meier C, Wegener I, Imbierowicz K, Conrad R, Liedtke R, Oldenburg J, Harbrecht U: Association between anxiety and factors of coagulation and fibrinolysis. Psychother Psychosom 2008;77:377-383.
64. Nemeroff CB, Musselman DL: Are platelets the link between depression and ischemic heart disease? Am Heart J 2000;140:57-62.
65. Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Mellédo JM: Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004;56:129-134. (Pubitemid 38844788)
66. Stafford L, Berk M: The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry 2011;72:1229-1235.
67. Portella MJ, de Diego-Adeliño J, Ballesteros J, Puigdemont D, Oller S, Santos B, Alvarez E, Artigas F, Pérez V: Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? a randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 2011;72:962-969.
68. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA: Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002;99:11946-11950. (Pubitemid 34994504)
69. Storkebaum E, Lambrechts D, Carmeliet P: VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004;26:943-954. (Pubitemid 39273068)
70. Warner-Schmidt JL, Duman RS: VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 2007;104:4647-4652. (Pubitemid 47186279)
71. Altar CA, Boylan CB, Jackson C, Hershenson S, Miller J, Wiegand SJ, Lindsay RM, Hyman C: Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc Natl Acad Sci USA 1992;89:11347-11351.
72. Iga JI, Ueno SI, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S, Nakataki M, Song H, Hokoishi K, Tanabe H, Sano A, Ohmori T: Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:658-663. (Pubitemid 46476822)
73. Kahl KG, Bens S, Ziegler K, Rudolf S, Kordon A, Dibbelt L, Schweiger U: Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 2009;34:353-357.
74. Dantzer R: Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 2009;29:247-64.
75. Liu Y, Ho RC, Mak A: Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and metaregression. J Affect Disord 2012;139:230-239.
76. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-457.
77. Garvey MA, Perlmutter SJ, Allen AJ, Hamburger S, Lougee L, Leonard HL, Witowski ME, Dubbert B, Swedo SE: A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biol Psychiatry 1999;45:1564-1571. (Pubitemid 29292832)
78. Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH: Antidepressant Response in Patients With Major Depression Exposed to NSAIDs: A Pharmacovigilance Study. Am J Psychiatry 2012;169:1065-1072.
79. Celano CM, Freudenreich O, Fernandez-Robles C, Stern TA, Caro MA, Huffman JC: Depressogenic effects of medications: a review. Dialogues Clin Neurosci 2011;13:109-125.
80. De Berardis D, Conti CM, Serroni N, Moschetta FS, Olivieri L, Carano A, Salerno RM, Cavuto M, Farina B, Alessandrini M, Janiri L, Pozzi G, Di Giannantonio M: The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol 2010;23:417-422.
81. Bell C, Abrams J, Nutt D: Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 2001;178:399-405. (Pubitemid 32436803)
82. Kamb ML, Murphy JJ, Jones JL, Caston JC, Nederlof K, Horney LF, Swygert LA, Falk H, Kilbourne EM: Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients. JAMA 1992;267:77-82.
83. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH: Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26:643-652. (Pubitemid 34260983)
84. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-684. (Pubitemid 43989814)
85. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A: Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009;26:607-611.
86. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL, Soares JC: Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008;23:87-94. (Pubitemid 351359580)
87. Guo JY, Li CY, Ruan YP, Sun M, Qi XL, Zhao BS, Luo F: Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 2009;612:54-60.
88. Gárate I, Garcia-Bueno B, Madrigal JL, Caso JR, Alou L, Gomez-Lus ML, Micó JA, Leza JC: Stress-induced neuroinflammation: role of the Toll-like receptor-4 pathway. Biol Psychiatry 2013;73:32-43.
89. Kumar B, Kuhad A, Chopra K: Neuropsychopharmacological effect of sesamol in unpredictable chronic mild stress model of depression: behavioral and biochemical evidences. Psychopharmacology (Berl) 2011;214:819-828.
90. Lau BW, Ren C, Yang J, Yan SW, Chang RC, Pu M, So KF: Light deprivation induces depression-like behavior and suppresses neurogenesis in diurnal mongolian gerbil (Meriones unguiculatus). Cell Transplant 2011;20:871-881.
91. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A: Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin J Psychiatry Neurosci 2012;37:7-16.
92. Ljubicić D, Stipcević T, Pivac N, Jakovljević M, Mück-Seler D: The influence of daylight exposure on platelet 5-HT levels in patients with major depression and schizophrenia. J Photochem Photobiol B 2007;89:63-69. (Pubitemid 350154467)
93. Ubbenhorst A, Striebich S, Lang F, Lang UE: Exploring the relationship between vitamin D and basic personality traits. Psychopharmacology (Berl) 2011;215:733-737.
94. Papadopoulos FC: Season as a possible confounding factor in reduced brain serotonin turnover following selective serotonin reuptake inhibitor therapy. Arch Gen Psychiatry 2008;65:1224-1225.
95. Thorn L, Evans P, Cannon A, Hucklebridge F, Clow A: Seasonal differences in the diurnal pattern of cortisol secretion in healthy participants and those with self-assessed seasonal affective disorder. Psychoneuroendocrinology 2011;36:816-823.
96. Molendijk ML, Haffmans JP, Bus BA, Spinhoven P, Penninx BW, Prickaerts J, Oude Voshaar RC, Elzinga BM: Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight. PLoS One 2012;7:e48046.
97. Goodman A, Paskins J, Mackett R: Day length and weather effects on children's physical activity and participation in play, sports, and active travel. J Phys Act Health 2012;9:1105-1116.
98. Wright KP, Rogers NL: Endogenous versus exogenous effects of melatonin; Pandi-Perumal, Cardinali (Eds.), Melatonin: from molecules to therapy, Nova Science Publishers, New York, 2007, pp 547-569.
99. Gonciarz M, Bielański W, Partyka R, Brzozowski T, Konturek PC, Eszyk J, Celiński K, Reiter RJ, Konturek SJ: Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatonin. J Pineal Res 2013;54:154-161.
100. Srinivasan V, Ohta Y, Espino J, Pariente JA, Rodriguez AB, Mohamed M, Zakaria R: Metabolic syndrome, its pathophysiology and the role of melatonin. Recent Pat Endocr Metab Immune Drug Discov 2013;7:11-25.
101. Martiny K, Refsgaard E, Lund V, Lunde M, Sørensen L, Thougaard B, Lindberg L, Bech P: A 9-week randomized trial comparing a chronotherapeutic intervention (wake and light therapy) to exercise in major depressive disorder patients treated with duloxetine. J Clin Psychiatry 2012;73:1234-1242.
102. Sanhueza C, Ryan L, Foxcroft DR: Diet and the risk of unipolar depression in adults: systematic review of cohort studies. J Hum Nutr Diet 2013;26:56-70.
103. Kim NH, Kim HS, Eun CR, Seo JA, Cho HJ, Kim SG, Choi KM, Baik SH, Choi DS, Park MH, Han C, Kim NH: Depression is associated with sarcopenia, not central obesity, in elderly korean men. J Am Geriatr Soc 2011;59:2062-2068.
104. Lyoo IK, Yoon S, Kim TS, Hwang J, Kim JE, Won W, Bae S, Renshaw PF: A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry 2012;169:937-945.
105. Yoshino S, Hara A, Sakakibara H, Kawabata K, Tokumura A, Ishisaka A, Kawai Y, Terao J: Effect of quercetin and glucuronide metabolites on the monoamine oxidase - A reaction in mouse brain mitochondria. Nutrition 2011;27:847-852.
106. Brüning CA, Souza AC, Gai BM, Zeni G, Nogueira CW: Antidepressant-like effect of m-trifluoromethyl-diphenyl diselenide in the mouse forced swimming test involves opioid and serotonergic systems. Eur J Pharmacol 2011;658:145-149.
107. Reynolds EH: Folic acid, ageing, depression, and dementia. BMJ 2002;324:1512-1515. (Pubitemid 34666626)
108. Mischoulon D, Raab MF: The role of folate in depression and dementia. J Clin Psychiatry 2007;68:28-33. (Pubitemid 47507835)
109. Almeida OP, Marsh K, Alfonso H, Flicker L, Davis TM, Hankey GJ: B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial. Ann Neurol 2010;68:503-510.
110. Lazarou C, Kapsou M: The role of folic acid in prevention and treatment of depression: an overview of existing evidence and implications for practice. Complement Ther Clin Pract 2010;16:161-166.
111. Martins JG, Bentsen H, Puri BK: Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis. Mol Psychiatry 2012;17:1144-1149.
112. Kornhuber J, Tripal P, Reichel M, Mühle C, Rhein C, Muehlbacher M, Groemer TW, Gulbins E: Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem 2010;26:9-20.
113. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M: S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a doubleblind, randomized clinical trial. Am J Psychiatry 2010;167:942-948.
114. O'Shea RD: Roles and regulation of glutamate transporters in the central nervous system. Clin Exp Pharmacol Physiol 2002;29:1018-1023. (Pubitemid 35177171)
115. Erecinska M, Silver IA: Metabolism and role of glutamate in mammalian brain. Prog Neurobiol 1990;35:245-296. (Pubitemid 20304100)
116. Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G: Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010;15:501-511.
117. Mineur YS, Picciotto MR, Sanacora G: Antidepressant-like effects of ceftriaxone in male C57BL/56J mice. Biol Psychiatry 2007;61:250-252. (Pubitemid 46072785)
118. Gourley SL, Espitia JW, Sanacora G, Taylor JR: Utility and antidepressant-like properties of oral riluzole in mice. Psychopharmacology 2012;219:805-814.
119. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr: A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793-802.
120. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS: mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959-964.
121. Lang UE, Heger J, Willbring M, Domula M, Matschke K, Tugtekin SM: Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement. Transplant Proc 2009;41:4285-4288.
122. Lauterbach EC: Dextromethorphan as a potential rapid-acting antidepressant. Med Hypotheses 2011;76:717-719.
123. Thase ME: Molecules That Mediate Mood. N Engl J Med 2007;357:2400-2402. (Pubitemid 350223397)
124. Pałucha A, Brański P, Szewczyk B, Wierońska JM, Kłak K, Pilc A: Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 2005;81:901-906. (Pubitemid 41187826)
125. Drevets WC, Furey ML: Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010;67:432-438.
126. Furey ML, Drevets WC: Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006;63:1121-1129. (Pubitemid 44498391)
127. Barragán-Rodríguez L, Rodríguez-Morán M, Guerrero-Romero F: Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial. Magnes Res 2008;21:218-223.
128. Sawada T, Yokoi K: Effect of zinc supplementation on mood states in young women: a pilot study. Eur J Clin Nutr 2010;64:331-333.
129. Schmidt HD, Duman RS: The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 2007;18:391-418. (Pubitemid 47356367)
130. Schmidt HD, Shelton RC, Duman RS: Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology. Neuropsychopharmacology 2011;36:2375-2394.
131. Campbell S, MacQueen G: An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry 2006;19:25-33. (Pubitemid 44406141)
132. Pittenger C, Duman RS: Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2007;33:88-109.
133. Schinder AF, Poo M: The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci 2000;23:639-645. (Pubitemid 32007891)
134. Aydemir O, Deveci A, Taneli F: The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:261-265. (Pubitemid 40202912)
135. Gervasoni N, Aubry JM, Bondolfi G, Osiek C, Schwald M, Bertschy G, Karege F: Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 2005;51:234-238. (Pubitemid 40976406)
136. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003;54:70-75. (Pubitemid 36776725)
137. Lee AH, Lange C, Ricken R, Hellweg R, Lang UE: Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J Clin Psychopharmacol 2011;31:334-336.
138. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM: Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002;109:143-148. (Pubitemid 34258493)
139. Kim YK, Lee HP, Won SD, Park EY, Lee HY, Lee BH, Lee SW, Yoon D, Han C, Kim DJ, Choi SH: Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:78-85. (Pubitemid 44959250)
140. Lee BH, Kim H, Park SH, Kim YK: Decreased plasma BDNF level in depressive patients. J Affect Disord 2006;101:239-244.
141. Brunoni AR, Lopes M, Fregni F: A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008;11:1169-1180.
142. Deuschle M, Gilles M, Scharnholz B, Lederbogen F, Lang UE, Hellweg R: Changes of Serum Concentrations of Brain-Derived Neurotrophic Factor (BDNF) during Treatment with Venlafaxine and Mirtazapine: Role of Medication and Response to Treatment. Pharmacopsychiatry 2013;46:54-58.
143. Ricken R, Adli M, Lange C, Krusche E, Koehler S, Hellweg R, Nase S, Richter C, Bschor T, Steinacher B, Rapp M, Borgwardt S, Lang UE: Reduced BDNF serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants. J Clin Psychopharmacol 2013; in press.
144. Sen S, Duman R, Sanacora G: Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64:527-532.
145. Lang UE, Günther L, Scheuch K, Klein J, Eckhart S, Hellweg R, Danker-Hopfe H, Oehler J: Higher BDNF concentrations in the hippocampus and cortex of an aggressive mouse strain. Behav Brain Res 2009;197:246-249.
146. Lang UE, Hellweg R, Gallinat J: Association of BDNF serum concentrations with central serotonergic activity: evidence from auditory signal processing. Neuropsychopharmacology 2005;30:1148-1153. (Pubitemid 40720973)
147. Lang UE, Hellweg R, Gallinat J: BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology 2004;29:795-798. (Pubitemid 38402487)
148. Lang UE, Hellweg R, Kalus P, Bajbouj M, Lenzen KP, Sander T, Kunz D, Gallinat J: Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berl) 2005;180:95-99. (Pubitemid 40897075)
149. Lang UE, Hellweg R, Seifert F, Schubert F, Gallinat J: Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol Psychiatry 2007;62:530-535. (Pubitemid 47284037)
150. Bauer M, Adli M, Bschor T, Pilhatsch M, Pfennig A, Sasse J, Schmid R, Lewitzka U: Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology 2010;62:36-42.
151. Hellweg R, Lang UE, Nagel M, Baumgartner A: Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats. Mol Psychiatry 2002;7:604-608.
152. Hock C, Heese K, Muller-Spahn F, Huber P, Riesen W, Nitsch RM, Otten U: Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression. Mol Psychiatry 2000;5:510-513.
153. Lang UE, Hellweg R, Bajbouj M, Gaus V, Sander T, Gallinat J: Gender-dependent association of a functional NGF polymorphism with anxiety-related personality traits. Pharmacopsychiatry 2008;41:196-199.
154. Smith MA, Makino S, Altemus M, Michelson D, Hong SK, Kvetnansky R, Post RM: Stress and antidepressants differentially regulate neurotrophin 3 mRNA expression in the locus coeruleus. Proc Natl Acad Sci USA 1995;92:8788-8792.
155. von Richthofen S, Lang UE, Hellweg R: Effects of different kinds of acute stress on nerve growth factor content in rat brain. Brain Res 2003;987:207-213. (Pubitemid 37281435)
156. Rosa AR, Frey BN, Andreazza AC, Cereser KM, Cunha AB, Quevedo J, Santin A, Gottfried C, Gonçalves CA, Vieta E, Kapczinski F: Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neurosci Lett 2006;407:146-150. (Pubitemid 44404148)
157. Evans SJ, Choudary PV, Neal CR, JZ, Vawter MP, Tomita H, Lopez JF, Thompson RC, Meng F, Stead JD, Walsh DM, Myers RM, Bunney WE, Watson SJ, Jones EG, Akil H: Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA 2004;101:15506-15511. (Pubitemid 39441571)
158. Beaulieu JM: A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. Psychopharmacol 2010;30:135-144.
159. Ackermann TF, Hörtnagl H, Wolfer DP, Colacicco G, Sohr R, Lang F, Hellweg R, Lang UE: Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala. Cell Physiol Biochem 2008;22:735-744.
160. Ackermann TF, Kempe DS, Lang F, Lang UE: Hyperactivity and enhanced curiosity of mice expressing PKB/ SGK-resistant glycogen synthase kinase-3 (GSK-3). Cell Physiol Biochem 2010;25:775-786.
161. Lang UE: Impairment of phosphatidylinositol 3-kinase signaling in schizophrenia: state or trait? Am J Psychiatry 2010;167:719.
162. Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Kessing LV: Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology (Berl) 2012;219:687-698.
163. Chengappa KN, Levine J, Gershon S, Mallinger AG, Hardan A, Vagnucci A, Pollock B, Luther J, Buttenfield J, Verfaille S, Kupfer DJ: Inositol as an add-on treatment for bipolar depression. Bipolar Disord 2000;2:47-55.
164. Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH: Doubleblind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995;152:792-794.
165. Eden Evins A, Demopulos C, Yovel I, Culhane M, Ogutha J, Grandin LD, Nierenberg AA, Sachs GS: Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord 2006;8:168-174. (Pubitemid 44026769)
166. Cattaneo A, Sesta A, Calabrese F, Nielsen G, Riva MA, Gennarelli M: The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology 2010;35:1423-1428.
167. Hunsberger JG, Newton SS, Bennett AH, Duman CH, Russell DS, Salton SR, Duman RS: Antidepressant actions of the exercise-regulated gene VGF. Nat Med 2007;13:1476-1482. (Pubitemid 350224242)